医学
内科学
心理干预
疾病
胃肠病学
并发症
肝病
血小板生成素
肝硬化
慢性肝病
重症监护医学
干细胞
遗传学
生物
造血
精神科
作者
Jinqin Qian,T T Yao,Yang Wang,G Q Wang
出处
期刊:PubMed
[National Institutes of Health]
日期:2021-09-20
卷期号:29 (9): 896-899
被引量:3
标识
DOI:10.3760/cma.j.cn501113-20200609-00304
摘要
Chronic liver disease causes bleeding and coagulation system abnormalities through a variety of mechanisms. Thrombocytopenia is a common complication of chronic liver disease. Patients with chronic liver disease, especially liver cirrhosis, often face more invasive examinations or surgeries, which brings great challenges to clinical diagnosis and treatment. Traditional platelet transfusion is the main clinical intervention. With the approval of thrombopoietin receptor agonists, the current management standards for chronic liver disease-related thrombocytopenia may face changes. This article reviews the current main non-pharmacological and pharmacological interventions for chronic liver disease-related thrombocytopenia, and put forwards the corresponding clinical management improvement strategies based on the efficacy and limitations of these interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI